Catalog #BP0075

InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1)

Clone RB6-8C5
Reactivities Mouse
Product Citations 36
Isotype Rat IgG2b, κ

$848.50 - $6,050.50

$848.50 - $6.00

Choose an Option...
  • 100 mg - $6,050.50
  • 50 mg - $4,277.50
  • 25 mg - $2,842.00
  • 5 mg - $848.50
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The RB6-8C5 monoclonal antibody reacts strongly with mouse Ly6G and weakly with mouse Ly6C previously referred to as GR-1. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Ly6G is expressed differentially during development by cells in the myeloid lineage including monocytes macrophages granulocytes and neutrophils. Monocytes typically express Ly6G transiently during development while mature granulocytes and peripheral neutrophils retain expression making Ly6G a good cell surface marker for these populations.The RB6-8C5 antibody has been shown to inhibit the binding of the 1A8 antibody. The 1A8 monoclonal antibody reacts specifically with mouse Ly6G with no reported cross reactivity with Ly6C.

Specifications

Isotype Rat IgG2b, κ
Recommended Isotype Control(s) InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Mouse granulocytes
Reported Applications in vivo depletion of Gr-1+ myeloid cells
Flow cytometry
Immunohistochemistry (paraffin)
Immunohistochemistry (frozen)
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin* ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Aggregation* <5%
Determined by SEC
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein G
RRID AB_10312146
Molecular Weight 150 kDa
Murine Pathogen Tests* Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options
* Additional quality control measures for our InVivoPlus™ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlus™ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlus™ difference here.

Application References

  • in vivo depletion of Gr-1+ myeloid cells
    Bansal, S., et al (2018). "IL-1 Signaling Prevents Alveolar Macrophage Depletion during Influenza and Streptococcus pneumoniae Coinfection" J Immunol 200(4): 1425-1433.

    Influenza and bacterial coinfection is a significant cause of hospitalization and death in humans during influenza epidemics and pandemics. However, the fundamental protective and pathogenic mechanisms involved in this complex virus-host-bacterium interaction remain incompletely understood. In this study, we have developed mild to lethal influenza and Streptococcus pneumoniae coinfection models for comparative analyses of disease pathogenesis. Specifically, wild-type and IL-1R type 1-deficient (Il1r1(-/-) ) mice were infected with influenza virus and then superchallenged with noninvasive S. pneumoniae serotype 14 (Spn14) or S. pneumoniae serotype 19A (Spn19A). The coinfections were followed by comparative analyses of inflammatory responses and animal protection. We found that resident alveolar macrophages are efficient in the clearance of both pneumococcal serotypes in the absence of influenza infection; in contrast, they are essential for airway control of Spn14 infection but not Spn19A infection. In agreement, TNF-alpha and neutrophils play a compensatory protective role in secondary bacterial infection associated with Spn19A; however, the essential requirement for alveolar macrophage-mediated clearance significantly enhances the virulence of Spn14 during postinfluenza pneumococcal infection. Furthermore, we show that, although IL-1 signaling is not required for host defense against pneumococcal infection alone, it is essential for sustaining antibacterial immunity during postinfluenza pneumococcal infection, as evidenced by significantly aggravated bacterial burden and animal mortality in Il1r1(-/-) mice. Mechanistically, we show that through preventing alveolar macrophage depletion, inflammatory cytokine IL-1 signaling is critically involved in host resistance to influenza and pneumococcal coinfection.

  • in vivo depletion of Gr-1+ myeloid cells Flow Cytometry
    Bodogai, M., et al (2015). "Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells" Cancer Res 75(17): 3456-3465.

    Myeloid-derived suppressive cells (MDSC) have been reported to promote metastasis, but the loss of cancer-induced B cells/B regulatory cells (tBreg) can block metastasis despite MDSC expansion in cancer. Here, using multiple murine tumor models and human MDSC, we show that MDSC populations that expand in cancer have only partially primed regulatory function and limited prometastatic activity unless they are fully educated by tBregs. Cancer-induced tBregs directly activate the regulatory function of both the monocyte and granulocyte subpopulations of MDSC, relying, in part, on TgfbetaR1/TgfbetaR2 signaling. MDSC fully educated in this manner exhibit an increased production of reactive oxygen species and NO and more efficiently suppress CD4(+) and CD8(+) T cells, thereby promoting tumor growth and metastasis. Thus, loss of tBregs or TgfbetaR deficiency in MDSC is sufficient to disable their suppressive function and to block metastasis. Overall, our data indicate that cancer-induced B cells/B regulatory cells are important regulators of the immunosuppressive and prometastatic functions of MDSC.

  • in vivo depletion of Gr-1+ myeloid cells
    Dahlgren, M. W., et al (2015). "T follicular helper, but not Th1, cell differentiation in the absence of conventional dendritic cells" J Immunol 194(11): 5187-5199.

    Development of long-lived humoral immunity is dependent on CXCR5-expressing T follicular helper (Tfh) cells, which develop concomitantly to effector Th cells that support cellular immunity. Conventional dendritic cells (cDCs) are critical APCs for initial priming of naive CD4(+) T cells but, importantly, also provide accessory signals that govern effector Th cell commitment. To define the accessory role of cDCs during the concurrent development of Tfh and effector Th1 cells, we performed high-dose Ag immunization in conjunction with the Th1-biased adjuvant polyinosinic:polycytidylic acid (pI:C). In the absence of cDCs, pI:C failed to induce Th1 cell commitment and IgG2c production. However, cDC depletion did not impair Tfh cell differentiation or germinal center formation, and long-lived IgG1 responses of unaltered affinity developed in mice lacking cDCs at the time point for immunization. Thus, cDCs are required for the pI:C-driven Th1 cell fate commitment but have no crucial accessory function in relation to Tfh cell differentiation.

  • in vivo depletion of Gr-1+ myeloid cells Flow Cytometry
    Wang, H., et al (2015). "P2RX7 sensitizes Mac-1/ICAM-1-dependent leukocyte-endothelial adhesion and promotes neurovascular injury during septic encephalopathy" Cell Res 25(6): 674-690.

    Septic encephalopathy (SE) is a critical factor determining sepsis mortality. Vascular inflammation is known to be involved in SE, but the molecular events that lead to the development of encephalopathy remain unclear. Using time-lapse in vivo two-photon laser scanning microscopy, we provide the first direct evidence that cecal ligation and puncture in septic mice induces microglial trafficking to sites adjacent to leukocyte adhesion on inflamed cerebral microvessels. Our data further demonstrate that septic injury increased the chemokine CXCL1 level in brain endothelial cells by activating endothelial P2RX7 and eventually enhanced the binding of Mac-1 (CD11b/CD18)-expressing leukocytes to endothelial ICAM-1. In turn, leukocyte adhesion upregulated endothelial CX3CL1, thereby triggering microglia trafficking to the injured site. The sepsis-induced increase in endothelial CX3CL1 was abolished in CD18 hypomorphic mutant mice. Inhibition of the P2RX7 pathway not only decreased endothelial ICAM-1 expression and leukocyte adhesion but also prevented microglia overactivation, reduced brain injury, and consequently doubled the early survival of septic mice. These results demonstrate the role of the P2RX7 pathway in linking neurovascular inflammation to brain damage in vivo and provide a rationale for targeting endothelial P2RX7 for neurovascular protection during SE.

Product Citations

  • Inhibiting the formation of neutrophil extracellular traps to prevent the recurrence of post-operative glioblastoma.

    In Nat Commun on 9 December 2025 by Han, Y., Han, M., et al.

    PubMed

    Glioblastoma (GBM) is a highly malignant tumor with a high postoperative recurrence rate. It is crucial to develop innovative and effective approaches to prevent its recurrence. Herein, we focus on the important roles of neutrophil extracellular traps (NETs) in the progression of GBM in mice and patients. Neutrophils accumulate around the surgical cavity and release NETs to promote the proliferation and migration of postoperative residual GBM cells. Injection of a hydrogel loaded with copper selenide nanozyme and doxorubicin into the surgical cavity successfully inhibit the formation of NETs and improve the therapeutic efficacy against GBM. 60% of treated GBM mice survive over 24 months, which are 36 times longer than those of untreated mice, and close to the lifespan of healthy mice. The treated mice preserve their essential cognitive functions and basic motor ability. This study demonstrates the great potential of modulating NETs in GBM therapy.

  • Depletion of myeloid cells in AG129 mice reduces the infection-mediated oxidative stress and restrains dengue virus-induced thymic atrophy.

    In Cell Commun Signal on 6 December 2025 by Kusuma, B., Rawat, S., et al.

    PubMed

    Infection-associated thymic atrophy is common and results in T-cell imbalance and immune dysfunction. Severe dengue, caused by infection with the dengue virus (DV), is associated with perturbation of T cell functions. However, it is unclear whether perturbation of T cell functions is linked to changes in thymic function during dengue infection.

  • An engineered human hepatitis A virus capable of rapid proliferation in vitro and causing hepatitis in mice.

    In JHEP Rep on 1 December 2025 by Li, J., Jiang, P. Y., et al.

    PubMed

    Hepatitis A virus (HAV) remains a significant public health threat. The HM175-mp4-based mouse model has advanced pathogenesis research, but its slow in vitro replication limits reverse genetic studies. We aimed to develop a genetically tractable HAV model through rational mutagenesis.

  • MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer.

    In Cell Rep Med on 15 July 2025 by Del Rey-Vergara, R., Galindo-Campos, M. A., et al.

    PubMed

    The introduction of immunotherapy as a first-line treatment for advanced small cell lung cancer (SCLC) represents significant progress, yet there remains an opportunity to further improve patient outcomes. Hepatocyte growth factor (HGF) receptor (MET) pathway activation promotes epithelial-mesenchymal transition, driving chemoresistance and potentially impairing the efficacy of immunotherapy. In SCLC mouse models, adding MET inhibition to chemo-immunotherapy (anti-PD-L1) reduces tumor growth, extends survival, and reshapes the tumor microenvironment by decreasing suppressive myeloid cell infiltration and enhancing the immune response. Analysis of pretreatment human SCLC tumor samples reveals that myeloid-enriched immune infiltrates may contribute to chemo-immunotherapy resistance. Elevated serum HGF levels are associated with a mesenchymal and inflamed phenotype, suggesting that patients with these characteristics might benefit from MET inhibitor-based therapeutic strategies. These findings provide strong preclinical and translational evidence supporting MET inhibition as a therapeutic approach to overcome treatment resistance, enhancing the immune response and improving outcomes in biomarker-defined subsets of SCLC patients.

Product FAQs

Related Products

  1. Catalog #BE0320
    InVivoMAb anti-mouse Ly6G/Ly6C Read more
  2. Catalog #CP135
    RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) Read more
  3. Catalog #CP172
    RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) Read more

Additional Formats

  1. Catalog #BE0075
    InVivoMAb anti-mouse Ly6G/Ly6C (Gr-1) Read more
  2. Catalog #CP135
    RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) Read more
  3. Catalog #CP172
    RecombiMAb anti-mouse Ly6G/Ly6C (Gr-1) Read more